Status:
COMPLETED
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007
Lead Sponsor:
Agios Pharmaceuticals, Inc.
Conditions:
Pyruvate Kinase Deficiency
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is an open-label, multicenter, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with mitapivat in participants who were previously enrolled in Study AG348...
Eligibility Criteria
Inclusion
- Be willing and able to comply with study visits and procedures.
- Have signed written informed consent prior to participating in this extension study.
- Have completed either antecedent study AG348-C-006 or AG348-C-007 through the Part 2 Week 24 Visit.
- Cohorts 2 and 3: Have demonstrated clinical benefit from mitapivat treatment in the antecedent study, in the opinion of the Investigator.
- For women of reproductive potential, have a negative pregnancy test during screening of this extension study.
- For women of reproductive potential as well as men with partners who are women of reproductive potential, be abstinent as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of study drug for women and 90 days following the last dose of study drug for men.
Exclusion
- Have a significant medical condition (including clinically significant laboratory abnormality) that developed during his/her antecedent AG- 348 study that confers an unacceptable risk to participating in this extension study, that could confound the interpretation of the study data, and/or that compromises the ability of the participant to complete study visits and procedures.
- Are currently pregnant or breastfeeding.
- Have a splenectomy scheduled during the study treatment period.
- Meet the withdrawal criteria of his/her antecedent mitapivat study during screening of this extension study.
- Are currently receiving medications that are strong inhibitors of cytochrome P450 (CYP)3A4 that have not been stopped for a duration of at least 5 days or a time frame equivalent to 5 half-lives (whichever is longer) before start of study drug; or strong inducers of CYP3A4 that have not been stopped for a duration of at least 28 days or a time frame equivalent to 5 half-lives (whichever is longer) before start of study drug on this extension study.
- Have received anabolic steroids, including testosterone preparations, within 28 days prior to start of study drug on this extension study.
- Have received hematopoietic stimulating agents (eg, erythropoietins, granulocyte colony stimulating factors, thrombopoietins) within 28 days prior to start of study drug on this extension study.
- Have exposure to any investigational drug other than mitapivat, device, or procedure within 3 months prior to start of study drug on this extension study.
Key Trial Info
Start Date :
March 21 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 3 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03853798
Start Date
March 21 2019
End Date
July 3 2024
Last Update
November 18 2025
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85016
2
UCSF Benioff Children's Hospital, Oakland
Oakland, California, United States, 95609
3
Emory-Children's Center
Atlanta, Georgia, United States, 30322
4
Indiana Hemophilia & Thrombosis Center Inc.
Indianapolis, Indiana, United States, 46260